NEWS

WIRES

OTHER

Kendall Law Group Plans Class Action on Behalf of Medivation, Inc. Shareholders

Any shareholder who purchased MDVN stock during this time period may move the Court to serve as a plaintiff in this class action. If you wish to serve as lead plaintiff, you must move the Court for appointment by May 8, 2010. A lead plaintiff is a class member who acts on behalf of other class members in directing the litigation. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff. If you wish to learn more about your rights as a shareholder or have information concerning this action, you are encouraged to contact attorney Hamilton Lindley at 877-744-3728 or hlindley@kendalllawgroup.com.

The complaint alleges violations of the federal securities laws for disseminating false and misleading public statements concerning the effectiveness of Dimebon, its progress toward FDA approval and market success. Before the market opened on March 3, 2010, Medivation disclosed that Dimebon had not met the primary and secondary goals in its Phase 3 trial. On this news, MDVN stock fell 67%, closing at $13.10 per share on March 3.

Kendall Law Group is a national securities firm that fights for shareholders when public companies break the law. Led by a former federal judge and former U.S. Attorney, Kendall Law Group has the credentials to pursue any type of complex securities litigation in the nation. Shareholders who purchased MDVN common stock during the relevant period may have a claim against the company and are urged to contact attorney Hamilton Lindley for more information:

Kendall Law Group LLP
Hamilton Lindley, 214-744-3000
214-744-3015 Facsimile
877-744-3728 Toll Free
hlindley@kendalllawgroup.com
www.kendalllawgroup.com